Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech A/S has entered into a significant option and license agreement with Merck Sharp & Dohme LLC, with the aim of leveraging Evaxion’s AI-driven vaccine antigen prediction technologies. The collaboration is set to advance the development and commercialization of next-generation immunotherapies and vaccines, particularly focusing on antigens for bacterial species in the genus Neisseria. This partnership marks a strategic move for both companies in their pursuit to innovate and deliver cutting-edge solutions in the pharmaceutical sector.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
